Eptifibatide

Molecular formula C35H49N11O9S2 Molecular weight 831.98 CAS Registry No 188627-80-7 Merck Index 13,3670 [Pg.228]

Sample preparation Dilute oral solution with MeCNrwater 70 30, inject a 100 (xL aliquot. [Pg.228]

Mobile phase Gradient. MeCN buffer 17 83 for 15 min, to 100 0 over 5 min, return to initial conditions over 2 min. (The buffer was 0.1% trifluoroacetic acid in water containing 0.1% triethylamine.) [Pg.228]

Yalkowsky, S.H. Stabilization of eptifibatide by cosolvents, Int.J.Pharm., 2001,218, 43-56. [Pg.228]

Mobile phase Gradient. MeCN water trifluoroacetic acid from 80 20 0.1 to 75 25 0.1 (sic) over 5 min. [Pg.228]

C3H7NO2S 52-90-4) see Carbocisteine Cilastatin Eptifibatide Letosteine Timonacic L-cysteine hydrochloride monohydrate... [Pg.2342]

C2H5NO2 56-40-6) see Eptifibatide Levodopa Loprazolam Stepronin Tiopronin glycine benzyl ester tosylate (CijHijNOjS 1738-76-7) see Acetorphan glycine potassium salt... [Pg.2391]

C6H14N2O2 56-87-1) see Eptifibatide Gusperimus trihydrochloride Ibuprofen lysinate Lisinopril Lymecycline... [Pg.2405]

The data for the use of GP Ilb/Illa inhibitors in conjunction with lAT are even more scant, and are limited to case reports. Intravenous abciximab has been successfully used as adjunctive therapy to lA rt-PA or UK in cases of acute stroke. Desh-mukh et al. reported on 21 patients with large vessel occlusion refractory to lAT with rt-PA who were treated with IV and/or lA abciximab, eptifibatide, or tirofiban. Twelve patients also received IV rt-PA and 18 patients underwent balloon angioplasty. Complete or partial recanalization was achieved in 17 of 21 patients. Three patients (14%) had asymptomatic ICH, but there were no cases of symptomatic ICH. Mangiafico et al. described 21 stroke patients treated with an intravenous bolus of tirofiban and heparin followed by lA urokinase. Nineteen of these patients also underwent balloon angioplasty. TIMI 2-3 flow was achieved in 17 of 21 patients. ICH occurred in 5 of 21 patients (3 symptomatic ICH and 2 SAH), and was fatal in 3... [Pg.79]

Ilia receptor either tirofiban or eptifibatide for patients Prior stroke... [Pg.93]

In patients with NSTE ACS scheduled for early PCI, administration of either abciximab or eptifibatide (double bolus) is recommended. The use of tirofiban in these patients is not recommended, because it has been shown to be inferior to abciximab.2 Medical therapy with glycoprotein Ilb/IIIa receptor inhibitors in patients not undergoing PCI is reserved for higher-risk patients, such as those with positive troponin or ST-segment depression, and patients who have continued or recurrent ischemia despite other antithrombotic therapy.2... [Pg.100]

Doses and contraindications to glycoprotein Ilb/IIIa receptor blockers are described in Table 5-2. Major bleeding and rates of transfusion are increased with administration of a glycoprotein Ilb/IIIa receptor inhibitor in combination with aspirin and an anticoagulant,30 but there is no increased risk of intracranial hemorrhage in the absence of concomitant fibrinolytic treatment. The risk of thrombocytopenia with tirofiban and eptifibatide appears lower than that with abciximab. Bleeding risks appear similar between agents. [Pg.100]

A 40- year-old female is to have angioplasty following an acute MI. As part of her treatment, she is given intravenously administered eptifibatide. What is the mechanism of action of eptifibatide ... [Pg.111]

Abciximab is preferred over eptifibatide and tirofiban in this setting because it is the most widely studied agent in primary PCI trials. [Pg.64]

Administration of tirofiban or eptifibatide is recommended for high-risk NSTE ACS patients as medical therapy without planned revascularization. [Pg.69]

Administration of either abciximab or eptifibatide is recommended for NSTE ACS patients undergoing PCI. [Pg.69]

Tirofiban and eptifibatide are also indicated in patients with continued or recurrent ischemia despite treatment with aspirin, clopidogrel, and an anticoagulant. [Pg.69]

Eptifibatide (Integrilin) Reteplase (Retavase) Ticlopidine (Ticlid) Tirofiban (Aggrastat)... [Pg.50]

See also in sourсe #XX -- [ Pg.102 , Pg.119 ]

See also in sourсe #XX -- [ Pg.150 ]

See also in sourсe #XX -- [ Pg.150 ]

See also in sourсe #XX -- [ Pg.367 ]

See also in sourсe #XX -- [ Pg.444 ]

See also in sourсe #XX -- [ Pg.102 , Pg.119 ]

See also in sourсe #XX -- [ Pg.154 , Pg.155 ]

See also in sourсe #XX -- [ Pg.150 ]

See also in sourсe #XX -- [ Pg.350 , Pg.353 ]

See also in sourсe #XX -- [ Pg.20 ]

See also in sourсe #XX -- [ Pg.41 , Pg.526 , Pg.529 , Pg.579 ]

See also in sourсe #XX -- [ Pg.763 ]

See also in sourсe #XX -- [ Pg.447 ]

See also in sourсe #XX -- [ Pg.486 , Pg.583 ]

See also in sourсe #XX -- [ Pg.167 ]

See also in sourсe #XX -- [ Pg.3 , Pg.3 , Pg.3 , Pg.29 , Pg.285 , Pg.318 ]

See also in sourсe #XX -- [ Pg.102 , Pg.119 ]

See also in sourсe #XX -- [ Pg.412 ]

See also in sourсe #XX -- [ Pg.31 , Pg.34 ]

See also in sourсe #XX -- [ Pg.234 ]

See also in sourсe #XX -- [ Pg.963 ]

See also in sourсe #XX -- [ Pg.275 ]

See also in sourсe #XX -- [ Pg.308 , Pg.310 ]

See also in sourсe #XX -- [ Pg.150 ]

See also in sourсe #XX -- [ Pg.269 , Pg.270 , Pg.273 ]

See also in sourсe #XX -- [ Pg.840 , Pg.841 ]

See also in sourсe #XX -- [ Pg.11 ]

See also in sourсe #XX -- [ Pg.703 ]

See also in sourсe #XX -- [ Pg.228 ]

See also in sourсe #XX -- [ Pg.393 , Pg.395 , Pg.396 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...